Results 261 to 270 of about 87,481 (331)
Hemodialysis‐associated radioactive waste management in [131I]I and [177Lu]Lu radionuclide therapy
Abstract Background Radionuclide therapy, such as with iodine‐131 or lutetium‐177–labeled substances, is used to treat thyroid cancer and neuroendocrine tumors. Due to the incorporated radioactivity, patients must remain hospitalized until radiation levels are deemed safe, according to national regulations. This is particularly problematic for patients
Dennis Kupitz +4 more
wiley +1 more source
N-Heterocyclic Carbenes as Ligands to <sup>198</sup>Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design. [PDF]
Spreckelmeyer S +10 more
europepmc +1 more source
This work explores ion‐selective organic electrochemical transistors for real‐time, long‐term potassium monitoring in the xylem sap of living trees. This bioelectronic approach provides new insights into plant physiology and has the potential to revolutionize forest, agricultural, and ecological monitoring for smarter, more sustainable plant management.
Sanggil Han +9 more
wiley +1 more source
Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications. [PDF]
Núñez-Salinas A +7 more
europepmc +1 more source
Radiolabeling of liposomes and polymeric micelles with PET-isotopes [PDF]
Jensen, Andreas Tue Ingemann
core
Harnessing chimeric antigen receptor macrophages against solid tumors
Abstract Macrophages are prevalent in multiple tumors and exhibit diverse and potent functional activities. Therapeutic reprogramming of macrophage phenotypes represents a promising strategy for cancer immunotherapy. Engineering chimeric antigen receptors (CARs) to endow macrophages with anti‐tumor capacities demonstrated encouraging efficacy ...
Mengru Wang +3 more
wiley +1 more source
<sup>166</sup>Dy/<sup>166</sup>Ho-labeled porous hydroxyapatite microparticles for treatment of inflammatory joint diseases - Exploring the advantages of in vivo generator. [PDF]
Patra S +6 more
europepmc +1 more source

